Healthcare / BiotechnologyKOSDAQ
$6590.00
+400.00 (+6.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-3.6B · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$80.2B
P/E
28.8x
↑EV/EBITDA
17.9x
↑ROE
9.7%
↑Gross Margin
61.0%
↑Debt/Equity
0.98
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+22.6%
FCF CAGR
—
FCF margin
4.2%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.67B · net income $2.79B · FCF $576.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.67B | $13.67B | $8.68B | $12.29B | $7.42B |
| Net Income | $2.79B | $2.79B | $-104.4M | $4.61B | $869.3M |
| EBITDA | $5.93B | $5.93B | $1.58B | $6.52B | $1.82B |
| EPS | 229.00 | 229.00 | -8.00 | 374.00 | 73.00 |
| Gross Margin | 61.0% | 61.0% | 68.2% | 70.3% | 60.8% |
| Operating Margin | 36.8% | 36.8% | -6.1% | 42.2% | 2.6% |
| Net Margin | 20.4% | 20.4% | -1.2% | 37.5% | 11.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.98 | 0.98 | 1.12 | 0.59 | 0.76 |
| Current Ratio | 10.81 | 10.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $576.6M | $576.6M | $-14.70B | $-3.64B | $-17.15B |
| Returns | |||||
| ROE | 9.7% | 9.7% | -0.4% | 16.4% | 3.6% |
| Valuation | |||||
| P/E | 28.78 | 28.78 | — | 28.66 | 146.58 |
| EV/EBITDA | 17.90 | 17.90 | 75.12 | 21.89 | 79.17 |
| P/B | 2.78 | 2.78 | 3.49 | 4.70 | 5.35 |
| Growth & Yield | |||||
| Revenue Growth | 57.5% | 57.5% | -29.4% | 65.7% | — |
| EPS Growth | 2962.5% | 2962.5% | -102.1% | 412.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
36.7%
EPS terminal req.
$584.75
Spread vs growth
2925.8%
5Y implied EPS CAGR
25.3%
EPS terminal req.
$707.55
Spread vs growth
2937.2%
10Y implied EPS CAGR
17.4%
EPS terminal req.
$1139.52
Spread vs growth
2945.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-8.00 → 229.00
Residual
-13.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.